Comunicado de la FDA sobre la seguridad de los medicamentos: Nuevo factor de riesgo para la leucoencefalopatía multifocal progresiva. Abstract. PASQUALOTTO, Alessandro Comarú; MATTOS, Alice J.Z. de and ROCHA, Marineide Melo. Leucoencefalopatia multifocal progressiva confirmada por. A leucoencefalopatia multifocal progressiva (LMP) é uma doença desmielinizante do sistema nervoso central (SNC) causada pela reativação do vírus JC (JCV).
|Published (Last):||11 December 2012|
|PDF File Size:||5.27 Mb|
|ePub File Size:||10.8 Mb|
|Price:||Free* [*Free Regsitration Required]|
Retrieved from ” https: Subcortical frontal and parieto-occipital regions are common locations. The most frequently encountered symptoms include:. The breakdown of myelin is commensurate with the degree of immunocompromise. J Neurol Neurosurg Psych ; There is a predilection for the parieto-occipital lobes. Muultifocal occurs almost exclusively in patients with severe immune deficiencymost commonly among patients with acquired immune deficiency syndrome AIDSbut people on chronic immunosuppressive medications including chemotherapy are also at increased risk of PML, such as patients with transplants, Hodgkin’s lymphomamultiple sclerosispsoriasisand other autoimmune diseases.
New insights on human polyomavirus JC and pathogenesis of progressive leicoencefalopatia leukoencephalopathy. In other projects Wikimedia Commons.
T2-weighted image reveals asymmetrical areas of hyperintensity, more marked in the left temporal region white arrows. Originally, PML was observed in patients with advanced HIV infection, lymphoproliferative disorders and transplant recipients. Shackelton; Andrew Rambaut; Oliver G.
Views Read Edit View history. Gislaine Cristina Lopes Machado Porto.
To quiz yourself on this article, log in to see multiple choice questions. JC virus granule cell neuronopathy: From Wikipedia, the free encyclopedia. The patient cleared the virus and had no further neurological deterioration.
Leucoencefalopatia Multifocal Progressiva (PML)
Corticosteroids have been used by several groups in order to modulate inflammatory reaction and avoid a catastrophic deterioration, but their use is controversial since they can also potentiate immunosuppression and blunt the JCV specific cellular immune response Please help improve this section by adding citations to reliable sources. This is in contradistinction to more symmetrical hypoattenuation seen in HIV encephalopathy. The cause of PML is a type of polyomavirus called the JC virus JCVafter the initials of the person from whose tissue the virus was first successfully cultured.
A number of drugs work against JC virus in cell culturebut no proven, effective therapy is known in humans. Retrieved 25 September Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: Its incidence increased fold and HIV infection quickly became the leading predisposing condition for the development of disease 1.
Unusual viral infections progressive multifocal leukoencephalopathy and cytomegalovirus disease after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. D ICD – Cerebrospinal fluid analysis was normal and serologic tests for herpes virus, syphilis, toxoplasmosis and HIV were all negative.
Progressive multifocal leukoencephalopathy | Radiology Reference Article |
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: J Neurol Neurosurg Psychiatry. Typically seen as multifocal, asymmetric periventricular leucoencefslopatia subcortical involvement. It is considered the most common clinical manifestation of John Cunningham virus JC virus infection in the brain 7and is seen in three clinical contexts:.
Poliomyelitis Demyelinating disease Transverse myelitis Tropical spastic paraparesis Epidural abscess. Herpes virus encephalitis should be considered in the initial phase, but white matter involvement is frequently temporal, bilateral and asymmetrical, with greater contrast enhancement than that found in PML. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients a report of 57 cases from the Research on Adverse Drug Events and Reports project.
Thereafter, the virus remains latent in the kidney, bone marrow and lymphoid organs, but, in a setting of cellular immunosuppression, the virus reactivates, spreads to the central nervous system CNSleading to infection of oligodendrocytes and demyelination 1. leucoemcefalopatia
Symptoms can develop over several weeks to months, and they depend on location of damage in the brain and the degree of damage. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. Progressive multifocal leukoencephalopathy in patients with HIV infection.
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. Archived from the original on 4 January A syndrome marked by progressive incoordination, dysarthria and cerebellar gait and atrophy of the cerebellum without white matter on MRI lesions occurs when a mutant virus with a 10 bp deletion mjltifocal the C terminus of the VP1 capsid protein infects the granule cell neurons.
Progressive multifocal leukoencephalopathy in non-HIV patient
Other findings include infected oligodendrocytes with enlarged amphophilic nuclei located at the periphery of the lesions, macrophages containing phagocytosed cellular debris and myelin, and reactive gliosis with enlarged astrocytes Therefore, treatment aims at reversing the immune deficiency to slow or stop the disease progress. Improvement in immunosuppression seems to be beneficial and can lead to stabilization or regression of the disease in follow-up on imaging exams.
While optic nerve or spinal cord lesion involvement is more suggestive of multiple sclerosis exacerbation and seizures were the presenting symptom of PML in several Natalizumab-treated patient, their occurrence should always raise suspicion of this condition. Histology reveals demyelinating plaques involving the white matter and subcortical U-fibers.
Improved survival of HIVinfected patients with progressive multifocal leukoencephalopathy receiving early leuceoncefalopatia combination antiretroviral therapy.